返回
Harnessing off-target effects
DOI:10.1038/nchembio.2519.png)
摘要
En 中文
The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action.
Keyword:
CHEMOTHERAPY
CERITINIB
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
13.7
论文数:
4.8K
被引数:
3.3W
机构
引用论文
SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group.
BMJ
IF0
Polypharmacology-based ceritinib repurposing using integrated functional proteomics
NATURE CHEMICAL BIOLOGY
IF13.7
Network pharmacology: the next paradigm in drug discovery网络药理学: 药物发现的下一个范式
NATURE CHEMICAL BIOLOGY
IF13.7
没有更多内容

